• Explore /
  • Poster
  • / Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).

Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

null

Neeraj Agarwal

University of Utah, Huntsman Cancer Institute, Salt Lake City, UT

Neeraj Agarwal , Kinjal Parikh , Srinivas Kiran Tantravahi , Hilda Crispin , Joan Van Atta , Julia Anne Batten , Daniel Sageser , Wolfram E. Samlowski , Kenneth F. Grossmann , Junfeng Wang , David D. Stenehjem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 461)

DOI

10.1200/jco.2014.32.4_suppl.461

Abstract #

461

Poster Bd #

E12

Abstract Disclosures

Similar Posters

First Author: Mayer N. Fishman

First Author: Leonard Joseph Appleman

First Author: Julia Anne Batten

First Author: Howard Kaufman